DigestRedComo funciona
Red
/
Empresas
Pa
No verificado

Palleon Pharmaceuticals

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaOncologíaSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
20/04/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
02/04/2026
Eventos
Industria
Oncología
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
22/10/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
Eventos
Palleon Pharmaceuticals to Present on Development of HLX79/E-602 in Autoimmune Disease at the American College of Rheumatology Convergence Annual Meeting and the American Society of Nephrology Kidney Week
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
07/08/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Industria
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
02/04/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
19/12/2024
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Mercado laboral
Industria
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0
08/11/2024
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fuente
Palleon Pharmaceuticals
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0